Close Menu

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis today reported that its full-year 2018 revenues rose 32 percent year over year, driven by instrument adoption in the US and European markets.

Biocartis also announced this morning that it had received CE-IVD marking for the Idylla MSI Test, which was previously available as a research-use only test called Idylla MSI Assay launched last July.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.